A multidisciplinary panel discusses the effects of GLP-1 RA use during breast cancer care along with insurance denials, costs, and other critical areas.

At the Big Ten CRC Summit, VK Gadi, MD, PhD, explained why functional drug testing and genomic profiling should be used ...

First-line pembrolizumab monotherapy did not significantly improve overall survival vs carboplatin plus paclitaxel at the first analysis in dMMR advanced or recurrent endometrial cancer.

Sacituzumab tirumotecan improved survival vs chemotherapy in patients with advanced or recurrent endometrial cancer after platinum and immunotherapy.

Oral vitamin C improved OS in patients with CCUS or lower-risk myeloid malignancies in the EVITA trial despite missing the clonal growth primary end point. Although the phase 2 EVITA trial ...